Sarcoma is one type of malignant tumor cancer that grows from tissues such as blood vessels, muscles, nerves, deep skin tissues, and fats. It arises at a body part that supports and protects surrounding the organs. Sarcoma is a life-threatening ailment when cancer has spread to the other body parts. At present, there are approximately 50 different forms of soft tissue sarcoma, including Malignant Mesenchymoma, Adult Fibrosarcoma, Clear Cell Sarcoma, Kaposi Sarcoma, Rhabdomyosarcoma, Angiosarcoma, and Alveolar soft-part sarcoma.
Soft tissue sarcoma can be identified with some diagnostic analysis such as PET scan, CT scan, ultrasound, biopsy, X-ray imaging, and MRI. Diagnostic tests including physical examination are used to diagnose the stages of soft tissue sarcoma, which is important to organize the treatment method. According to the American Cancer Society, approximately 12,390 new patients with soft tissue sarcoma were estimated to be diagnosed in the U.S. by the end of 2017 and approximately 55% of the cases are reported to be diagnosed with sarcoma in male population. Moreover, according to the same reports around 5150 Americans are expected to die due to soft tissue sarcoma during the upcoming year. Few of the medications used to treat soft tissue sarcoma include Doxorubicin (Adriamycin), Trabectedin (Yondelis), Bevacizumab (Avastin), Sirolimus (Rapamune), and, Sunitinib (Sutent), among others.
Increasing occurrence of sarcoma cancer demanding proper treatment to boost the market for Soft Tissue Sarcoma Treatment
Increasing number of people suffering from soft tissue sarcoma is anticipated to boost the soft tissue sarcoma treatment market growth. In addition, major factors driving the global market growth include growing research and development infrastructure, targeted drug therapies for oncology treatment along with the enhanced expiration of patents. The rise in spending on healthcare for appropriate patient care and several advanced treatments are other factors bolstering the growth of global market. In addition, increasing focus on adapted medication along with enormous assets for anti-cancer treatment research is expected to reveal new paths for soft tissue sarcoma treatment market during the forecast period.
However, high cost for treatment and medication along with associated side effects are factors which might hamper the market growth. Moreover, the high cost of diagnostics including radiation therapy, chemotherapy, stringent government regulation, and the high failure rate are challenges anticipated in this market.
The Global Soft Tissue Sarcoma Treatment Market is segmented on the basis of treatment, end user, and geography.
On the basis of treatment, market is segmented into
On the basis of end user, market is segmented into
Geographically, this market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Asia Pacific region expected to witness dominating growth due to increased spending intended for oncology diagnosis
On the basis of geography, North America is estimated to dominate the soft tissue sarcoma treatment market. The major market share is majorly due to a high prevalence rate of oncology case in this region. According to the American Cancer Society, more than 10,500 cases of soft tissue sarcoma, or 2% of all cancers, are diagnosed in the United States each year. Slightly more than half of these are in males. Thus, high occurrence, demanding proper care and medication is anticipated to bolster the soft tissue sarcoma treatment market in this region. However, Asia-Pacific region is anticipated to make a significant growth during the forecast period. Increasing cancer cases and increasing consciousness about advanced cancer treatments are the factors expected to enhance the market in the Asia Pacific. In addition, growing healthcare spending associated with cancer and related disease is projected to boost the market growth during the forecast period.